HNWAG
TNYA icon

High Net Worth Advisory Group’s Tenaya Therapeutics TNYA Stock Holding History

High Net Worth Advisory Group’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$19K – 729
2021
Q4 		$19K Buy
+1,000
New +$21.8K 0.01% 471

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

High Net Worth Advisory Group's TNYA Position: Q1 2022 in Review

High Net Worth Advisory Group sold out of Tenaya Therapeutics (TNYA) in Q1 2022, closing a stake of 1,000 shares — an estimated $19K sold.

High Net Worth Advisory Group first reported a position in TNYA in Q4 2021 and held it in 1 quarter. The position peaked at $19K in Q4 2021. 50 funds tracked by Wall St. Rank hold TNYA as of Q1 2022.

  • High Net Worth Advisory Group reported no remaining Tenaya Therapeutics position as of Q1 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Tenaya Therapeutics shares in Q1 2022, an estimated $19K.
  • High Net Worth Advisory Group first reported a position in Tenaya Therapeutics in Q4 2021 and held it in 1 quarter.
  • High Net Worth Advisory Group's Tenaya Therapeutics position peaked at $19K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2022.

Based on High Net Worth Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.